p53 at the crossroads of MPN treatment

Abstract

In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).1 © 2014 by The American Society of Hematology.